Imagine a World Where metabolic balance is the norm,And patients live without compromise. " We are developing and delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families. learn more Our lead development program: two Phase 3 programs in congenital and tumor hyperinsulinism. View Our Pipeline Check out stories about how patients and their families address the day-to-day challenges of living with hyperinsulinism. View patient Voices Recent Press Releases view all Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society 06/17/26 Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society 06/04/26 Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism 06/02/26
